Suchergebnisse - "Meyer, Antoine"

PubPharm (9)

1

Maternal Exposure to Anti-TNF or Thiopurines for IBD Does Not Increase Risk of Early-life Malignancy in Children

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2023

von Meyer, A. | Rios, P. | Drouin, J. | +3

2

Benefits and Risks Associated With Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease : A Nationwide Emulation Trial

enthalten in: Annals of internal medicine | 2022

von Meyer, A. | Neumann, A. | Drouin, J. | +3

CommentIn: Gastroenterology. 2023 Jun;164(7):1336-1337. - PMID 36608718

3

Serious Infections in Children Born to Mothers With Inflammatory Bowel Disease With In Utero Exposure to Thiopurines and Anti-Tumor Necrosis Factor

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2022

von Meyer, A. | Taine, M. | Drouin, J. | +3

4

Systematic review with meta-analysis : the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor

enthalten in: Alimentary pharmacology & therapeutics | 2022

von Parrot, L. | Dong, C. | Carbonnel, F. | +1

5

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF

enthalten in: RMD open | 2022

von Cachen, L. | Nocturne, G. | Collins, M. | +6

6

The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2020

von Kassouri, L. | Amiot, A. | Kirchgesner, J. | +6

7

Systematic review with meta-analysis : comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease

enthalten in: Alimentary pharmacology & therapeutics | 2020

von Chupin, A. | Perduca, V. | Meyer, A. | +3

8

Letter : choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply

enthalten in: Alimentary pharmacology & therapeutics | 2020

von Alric, H. | Amiot, A. | Carbonnel, F. | +1

CommentOn: Aliment Pharmacol Ther. 2020 Apr;51(8):789-800. - PMID 32133656

9

The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor

enthalten in: Alimentary pharmacology & therapeutics | 2020

von Alric, H. | Amiot, A. | Kirchgesner, J. | +6

CommentIn: Aliment Pharmacol Ther. 2020 Aug;52(3):561-562. - PMID 32656826

1
[1]